Tirzepatide

A dual GLP‑1/GIP receptor agonist approved for type 2 diabetes (brand name Mounjaro) with significant weight-loss benefits. It enhances insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite more effectively than GLP‑1 monotherapies. Clinical trials show superior glycemic control and body weight reduction in obesity treatment.

References

Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., … & Kaufman, K. D. (2021). Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519

Price range: $175.00 through $225.00

Tirzepatide

Related Products

Related products

Scroll to Top